HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR by Ingthorsson, Saevar et al.
OPEN
ORIGINAL ARTICLE
HER2 induced EMT and tumorigenicity in breast epithelial
progenitor cells is inhibited by coexpression of EGFR
S Ingthorsson1,2, K Andersen3,4, B Hilmarsdottir1,2, GM Maelandsmo3,4,5, MK Magnusson1,2,6 and T Gudjonsson1,2
The members of the epidermal growth factor receptor (EGFR) kinase family are important players in breast morphogenesis and cancer.
EGFR2/HER2 and EGFR expression have a prognostic value in certain subtypes of breast cancer such as HER2-ampliﬁed, basal-like and
luminal type B. Many clinically approved small molecular inhibitors and monoclonal antibodies have been designed to target HER2,
EGFR or both. There is, however, still limited knowledge on how the two receptors are expressed in normal breast epithelium, what
effects they have on cellular differentiation and how they participate in neoplastic transformation. D492 is a breast epithelial cell line
with stem cell properties that can undergo epithelial to mesenchyme transition (EMT), generate luminal- and myoepithelial cells and
form complex branching structures in three-dimensional (3D) culture. Here, we show that overexpression of HER2 in D492 (D492HER2)
resulted in EMT, loss of contact growth inhibition and increased oncogenic potential in vivo. HER2 overexpression, furthermore,
inhibited endogenous EGFR expression. Re-introducing EGFR in D492HER2 (D492HER2/EGFR) partially reversed the mesenchymal state of
the cells, as an epithelial phenotype reappeared both in 3D cultures and in vivo. The D492HER2/EGFR xenografts grow slower than the
D492HER2 tumors, while overexpression of EGFR alone (D492EGFR) was not oncogenic in vivo. Consistent with the EGFR-mediated
epithelial phenotype, overexpression of EGFR drove the cells toward a myoepithelial phenotype in 3D culture. The effect of two
clinically approved anti-HER2 and EGFR therapies, trastuzumab and cetuximab, was tested alone and in combination on D492HER2
xenografts. While trastuzumab had a growth inhibitory effect compared with untreated control, the effect of cetuximab was limited.
When administered in combination, the growth inhibitory effect of trastuzumab was less pronounced. Collectively, our data indicate
that in HER2-overexpressing D492 cells, EGFR can behave as a tumor suppressor, by pushing the cells towards epithelial differentiation.
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INTRODUCTION
Carcinomas of the breast can be classiﬁed by their intrinsic gene
expression pattern, and the phenotype of the various tumor
subtypes has been postulated to mimic speciﬁc differentiation
stages within breast development.1,2 It has been demonstrated
that luminal cancers show a gene expression pattern consistent
with the differentiated luminal compartment, while the HER2
(EGFR2, ErbB2) and triple negative subgroups show a more
undifferentiated expression pattern. This is consistent with the
tumor subgroups to arise from luminal and basal-like progenitor
cells, respectively.3,4
How various critical oncogenic signals affect the differentiation
state and thus affect the breast cancer subgrouping is still not well
known. The reason for this is partly the lack of in vitro culture
systems, modeling both normal breast stem cell biology and
neoplastic transformation. D492 is a breast epithelial cell line with
stem cell properties that was established by isolating and
immortalizing a MUC1−, EpCAM+ suprabasal cell population from
normal primary tissue.5 D492 cells differentiate into both luminal-
and myoepithelial cells and form branching bi-layered cellular
structures resembling the terminal duct lobular units when
cultured in reconstituted basement membrane matrix (rBM).
Furthermore, these cells can respond to microenvironmental
signals to undergo epithelial to mesenchyme transition (EMT).6
EMT is a pivotal step during cancer progression where cells
acquire motility by losing epithelial characteristics such as
expression of cytokeratins and E-cadherin, and gain expression
of mesenchymal markers, like vimentin, ﬁbronectin and N-cad-
herin (reviewed by Moyret-Lalle et al.7). Changes in microRNA
(miR) expression, such as the miR-200 members, have also been
implicated with EMT in breast cancer.8–11 Given phenotypic
ﬂexibility and the stem cell nature of the D492 cells, they have a
unique potential to model the effect of critical signaling molecules
on cellular morphogenesis, differentiation, EMT and neoplastic
transformation.
Dysregulation of the signaling pathways activated by the
epidermal growth factor receptor (EGFR) family is oncogenic in
many epithelial cells. Ampliﬁcation of the HER2 (ErbB2) gene is
especially injurious in breast epithelium where upregulation of
HER2 is seen in approximately 20% of all breast cancers,12 leading
to increased proliferation, cell motility and metastasis.13 These
receptors are also key components in controlling polarization and
cellular differentiation of the breast gland (reviewed by Sternlicht
et al.14).
The clinical effects of HER2 and EGFR dysregulation are well
known, and a range of options for inhibiting their adverse effects
exists.15 New breast cancer treatment regimens have, however,
actualized new clinical challenges. Development of resistance
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against EGFR family-targeted therapy is common, and in the HER2
breast cancer subgroup, systemic disease is now partially
controlled, while metastatic disease in the central nervous system
seems to escape both targeted and conventional therapy.16
Increased understanding how HER2 and EGFR signaling affects
cellular behavior and differentiation in breast epithelial cells is
therefore needed. The objective of this study was to address the
functional consequences of HER2 and EGFR overexpression in
breast epithelial progenitor cells focusing on both cellular
differentiation and tumorigenicity. In vitro three-dimensional
(3D) models and in vivo tumorigenicity assays were employed to
measure changes in cellular phenotype, stemness and tumor-
initiating ability.
RESULTS
HER2 and EGFR show distinct expression pattern in human breast
epithelium
Initially, we analyzed HER2 and EGFR expression in the
normal breast. CK19 and CK14 were used to identify luminal
epithelial- and myoepithelial cells, respectively (Figure 1, top
left). Co-staining of EGFR and HER2 with either CK19 or CK14
revealed distinct expression patterns with EGFR expression
associated with the basal/myoepithelial compartment. HER2
expression was predominantly associated with the luminal
epithelial cells (Figure 1, lower right). Co-staining of EGFR and
HER2 revealed cells within the myoepithelial compartment being
positive for both receptors (Figure 1, top right). Western blotting
of isolated primary luminal- and myoepithelial cells from
reduction mammoplasties conﬁrmed a higher expression of
HER2 in luminal epithelial cells compared with myoepithelial
cells, and more EGFR in myoepithelial cells (Figure 1b) compared
with luminal cells.
Overexpression of HER2 in D492 breast epithelial progenitor cell
line leads to reduced EGFR expression and EGF-independent
activation of EGFR and HER2
Corresponding to the basal-like phenotype of D4926,17 the cells
express very low levels of HER2 (Figures 2a and b). To analyze the
Figure 1. Expression of EGFR and HER2 in normal human breast gland. (a) HER2 and EGFR are expressed in luminal and myoepithelial cells,
respectively. Confocal microscopy images of human mammary gland tissue sections. The sections were stained with antibodies against CK19,
CK14, EGFR and HER2 in various combinations, and the images show part of an intralobular duct. Cytokeratin 19 and 14 (top left) identify
luminal and myoepithelial cells, respectively. Bar= 50 μm. (b) Expression of EGFR and HER2 in cultured primary breast epithelial cells. Western
blot of lysates made from puriﬁed primary myoepithelial (MEP) and luminal (LEP) epithelial cells from normal human mammary gland, stained
with antibodies against EGFR, HER2, CK14 and CK19. GAPDH= loading control.
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Figure 2. HER2 overexpression reduces EGFR expression. (a) Expression of endogenous EGFR in D492HER2 is reduced compared with D492ctrl.
Confocal microscopy images of D492 cells expressing ctrl, HER2, EGFR and HER2/EGFR grown on culture ﬂasks and analyzed by
immunoﬂuorescence staining for EGFR and HER2 expression. Bar= 50 μm. (b) HER2 overexpression leads to reduced EGFR transcription levels.
Quantitative reverse transcriptase–PCR was performed using monolayer RNA isolates from all four cell lines. Transcription of HER2 and EGFR
was analyzed, and normalized to GAPDH. (c) HER2 overexpression leads to ligand-independent EGFR and HER2 phosphorylation. Cells on
monolayer were starved for 24 h in media without EGF. Cells were then given control media or EGF-containing culture media. Protein lysates
were collected at +180min and blotted for total and phosphorylated EGFR and HER2. Actin= loading control.
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differentiation- and oncogenic potential of HER2 on mammary
progenitor cells, the protein was overexpressed in D492
(Supplementary Figure S1). HER2 transduction (D492HER2) resulted
in high expression at both protein (Figure 2a) and transcriptional
level (Figure 2b). Interestingly, endogenous EGFR expression was
greatly reduced in the D492HER2 cells; reduced staining of
EGFR (Figure 2a) correlates well with reduced transcription of
the EGFR gene (Figure 2b). Transduction of EGFR into D492HER2
(D492HER2/EGFR) partially restored EGFR expression (Figure 2a).
Quantitative reverse transcriptase–PCR was performed to conﬁrm
that the reduced EGFR levels was caused by transcriptional
repression of EGFR mRNA (Figures 2a and b).
To investigate whether overexpression of HER2 led to changes
in the activation state of the two receptors, cells were starved
and then treated with EGF for up to 3 h. In the absence of EGF, no
phosphorylation of either tyrosine (Y)1173 or 1068 on EGFR was
detected in D492ctrl and D492EGFR. In contrast, while strong EGFR
downregulation could be seen in D492HER2, the cells show
detectable EGFRY1068 and HER2Y1221/1222 phosphorylation,
demonstrating EGF-independent activation of both receptors
(Figure 2c). Upon addition of EGF, strong phosphorylation at
Y1173 and Y1068 was detected after 3 and 30 min in both
D492ctrl and D492EGFR cells (Supplementary Figure S2). This signal
was maintained after 3 h (Figure 2c). Interestingly, in D492HER2
cells the response to EGF treatment was much less pronounced,
presumably in part due to the reduced EGFR levels. Phosphor-
ylation of Y1068 showed minimal change, and Y1173 phosphor-
ylation returned to baseline levels within 3 h. Phosphorylation of
HER2 could be detected in HER2-expressing cells, and did not
respond to EGF treatment. These data demonstrate that HER2
overexpression in D492 made the cells EGF independent and
nonresponsive to EGF.
HER2-induced EMT in D492 cells
The effect of EGFR and HER2 overexpression on the cellular
differentiation status was evaluated by measuring the expression
of epithelial (CK14, CK19, E-cadherin, p63, P-cadherin) and
mesenchymal (N-cadherin and Axl) markers in the transduced
cell lines. D492HER2 cells showed a near complete loss of CK14 and
CK19, E, and P-cadherin and p63 (Figure 3a, upper right), while
partial re-expression of the four markers was seen in D492HER2/EGFR
(Figure 3a, lower right). D492EGFR showed a heterogeneous
expression pattern of CK19 and CK14, comparable to the control
cell line, with most cells being either CK19 positive or CK14
positive while a smaller subpopulation was double positive
(Figure 3a, lower left). In D492EGFR no change in E-cadherin
expression was seen, but expression of P-cadherin was increased,
suggesting increased myoepithelial differentiation. The overall
expression of luminal-, myoepithelial and mesenchymal markers
in the cell lines was also compared using western blotting
(Figure 3b). The loss of epithelial markers was conﬁrmed in both
D492HER2 and D492HER2/EGFR as evidenced by reduced expression
of P63, CK14 and CK19 as well as E- and P-cadherins. Furthermore,
these cells showed increased mesenchymal marker expression as
shown by immunostaining with N-cadherin and Axl, indicating
that HER2-overexpressing D492 cells have switched to a more
mesenchymal phenotype (Figure 3b). D492EGFR, on the other
hand, showed a more pronounced basal/myoepithelial differen-
tiation, as evidenced by stronger CK14, P63 and P-cadherin
expression and loss of CK19 (Figure 3b). It is well known that the
miR-200 family regulates epithelial morphogenesis and EMT
through a negative feedback loop with the ZEB1 and ZEB2
transcription factors.11 Compared with D492ctrl, the miR-200c-
miR141 cluster was greatly downregulated in D492HER2 cells
(Figure 3c), accompanied with upregulation of ZEB1. Constitutive
expression of EGFR, on the other hand, with or without HER2
resulted in increased miR-200-141 expression levels, and reduced
ZEB1 (Figure 3c). Collectively, the results indicated that the
tyrosine kinases EGFR and HER2 had distinct effects on
differentiation in the breast epithelial progenitor cell line D492.
Introduction of HER2 caused a loss of EGFR, cytokeratins and
E-cadherin, and increased expression of mesenchymal markers
indicating that the cells underwent EMT.
Expression of HER2 leads to non-adherent growth
D492ctrl cells are growth inhibited when they reach conﬂuency in
two-dimensional culture. EGFR overexpression affected the
growth pattern only to a limited degree (Figure 4a), while
D492HER2 and D492HER2/EGFR cells had lost their contact inhibition
and continued to proliferate after reaching conﬂuency, piling up
in culture. (Figure 4a). Increased fraction of non-viable cells was
not detected, and all sublines exhibited 95% and higher viability
after 12 days in culture. Furthermore, as colonies of viable cells
could be seen ﬂoating in the culture medium, we seeded cells into
low-attachment plates and quantiﬁed survival based on colony
formation (Figure 4b). In this environment, a subset of D492ctrl
cells was able to survive and proliferate, forming small spheroid
clusters (Figure 4b, GFP images). D492EGFR did not have
signiﬁcantly higher number of spheroids formed compared with
D492ctrl, but the size of the spheres was signiﬁcantly increased.
D492HER2 and D492HER2/EGFR showed greatly increased sphere
formation. In addition, they were not spherical with intact cell–cell
adhesion as seen in D492ctrl and D492EGFR cells, instead the
spheres appeared to form grape-like aggregates, perhaps
indicative of changed cell–cell adhesion properties (Figure 4b,
bottom GFP images).
HER2 maintained a mesenchymal phenotype in 3D culture that
was partially restored by re-expression of EGFR
Considering the effects of HER2 overexpression on loss of contact
inhibition and epithelial markers, it was interesting to compare the
phenotypes of all four cell lines when cultured in rBM. The three
cell lines that expressed EGFR (ctrl, EGFR and HER2/EGFR)
predominantly formed structures with a solid epithelial phenotype
with robust cell–cell adherence and some budding/branching
structures (Figure 5a). To test the differentiation status of the
different 3D phenotypes, immunostaining showed that budding/
branching and round structures expressed epithelial markers,
while grape like and spindle did not (Figure 5a). D492HER2 cells in
rBM showed a diffuse phenotype containing almost only grape- or
spindle-like structures. To see whether HER2 receptor signaling
was crucial for formation of these mesenchymal colony-type
structures, cultures were treated with the HER2 inhibitor
CP724,714 (CP). Spindle colony formation was completely
inhibited in all cultures when CP treated (Figure 5a, table panel).
Furthermore, CP-treated D492HER2 cells formed more solid round
spheres. These results indicated that HER2 expression is essential
for the mesenchymal phenotype to appear, and that EGFR had a
stronger effect on morphology in 3D rBM than in monolayer.
Western blotting of lysates from 3D rBM cultures was performed
to check whether the EGFR induced appearance of epithelial
structures in 3D coincided with re-expression of epithelial markers.
Cytokeratins 14 and 19 and E-cadherin were expressed in all EGFR-
expressing cell lines in 3D rBM (Figure 5b). The observation that
EGFR expression partially reverses HER2-induced EMT in 3D
culture but not in monolayer (compare western blots in
Figure 3b with Figure 5b) emphasizes how vastly different
these culture conditions are. On the one hand, cells are grown
on 2D collagen-coated plastic, while in the other, cells are
embedded in 3D laminin-rich extracellular matrix. In 2D culture, no
N-cadherin staining is seen in control cells, while in 3D culture
control cells express N-cadherin, indicating a partial switch in
phenotype (Figure 5b). It is increasingly being recognized that
signaling and gene expression is regulated differently in 3D
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compared with 2D culture.18 These data indicate that EGFR
partially inhibits the HER2-induced mesenchymal phenotype with
re-appearance of cytokeratins and E-cadherin, in addition to
promoting epithelial morphology in 3D cultures.
Ectopic expression of EGFR attenuates HER2-induced
tumorigenicity in D492
To test whether EGFR, HER2 or double overexpression of these
two receptors affected growth in vivo, the four cell lines were
Figure 3. HER2 overexpression induces mesenchymal transition. (a) D492HER2 cells lose epithelial phenotype in monolayer culture. Confocal
microscopy images of D492 cells expressing ctrl, HER2, EGFR and HER2/EGFR grown on culture ﬂasks and analyzed by immunoﬂuorescence
staining for CK14, CK19, E-, N- and P-cadherin expression. Bar= 50 μm. (b) D492HER2 and D492HER2/EGFR gain mesenchymal phenotype in
monolayer culture. Western blotting performed using lysates from monolayer cultures. Membranes were blotted for CK14, CK19, p63, E-,
P-, N-cadherin and Axl expression. Actin= Loading control. (c) In D492HER2, miR-200c and miR141 are strongly downregulated. Quantitative
reverse transcriptase–PCR was performed using monolayer RNA isolates from all four cell lines. Transcription of miR-200c, miR-141 and
ZEB1was analyzed and normalized to GAPDH.
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injected into mammary fat pads of NSG mice. With variable
efﬁciency, all cell lines gave rise to small but palpable tumors
1 week post injection (Figure 6a). HER2 overexpression gave rise to
fast growing tumors, while tumors from D492ctrl and D492EGFR
ceased to grow (Figure 6b). Interestingly, and in good con-
cordance with our 3D data, D492HER2/EGFR tumors had a longer lag
period, and did not grow as fast as D492HER2, indicating that EGFR
expression suppressed the growth-promoting effect of HER2
(Figure 6b and Supplementary Figure S2A). Based on these
ﬁndings it was interesting to test whether inhibition of EGFR
signaling in HER2-expressing cells would affect tumor growth.
D492HER2 tumor-bearing animals were treated with trastuzumab
(HER2 mAB/Herceptin), cetuximab (EGFR mAb/Erbitux) or a
combination of the two, and changes in tumor volume were
monitored. Upon trastuzumab treatment, tumors decreased
signiﬁcantly in size compared with control, and although some
of the individual tumors seemed to regain growth after a lag
period, trastuzumab had a clear growth inhibitory effect
(Supplementary Figure S4). Interestingly, when administered in
combination with cetuximab, the effect of the anti-HER2 mab was
less pronounced, as the tumors in this group had a shorter lag
period and after 30 days of treatment, they grew equally fast as
the control tumors, suggesting that inhibition of EGFR generated
faster growth and/or reduced the sensitivity to trastuzumab
(Figure 6c). Cetuximab alone induced a brief pause in tumor
growth but after 20 days the related tumors regained a growth
rate comparable to the control tumors. The observed in vivo
effects of HER2 overexpression and inhibition made it interesting
to investigate the patterns of receptor and marker expression
within the xenograft tumors. Sections of immunoﬂuorescently-
stained D492HER2 and D492HER2/EGFR tumors showed that the
in vivo expression of epithelial markers correlated well to the 3D
in vitro phenotype (Figure 7). D492HER2 cells expressed HER2 but
had low EGFR expression. Furthermore, they were CK14 negative
demonstrating lack of myoepithelial differentiation and were also
E-cadherin and CK19 negative (Figure 7b and Supplementary
Figure S3B) In contrast, D492HER2/EGFR formed tumors that were
heterogeneous in terms of marker expression. These tumors were
positive for both HER2 and EGFR with HER2 expressed in all tumor
cells, whereas EGFR was partially lost. CK14 expression was
restricted to EGFR-expressing cells, thus indicating retention of
epithelial characteristics within these tumors (Figure 7b). Addi-
tionally, E-cadherin and CK19 staining were seen in EGFR-
expressing cells (Figure 7 and Supplementary Figures S3 and
S5). Ki67 staining in HER2 and HER2/EGFR tumors was comparable,
but markedly higher than in control or EGFR tumors (Figure 7c and
Supplementary Figure S3B, respectively). Interestingly, staining for
cleaved caspase-3 indicated that apoptosis levels were consider-
ably higher in HER2/EGFR tumors compared with HER2 alone.
Incidentally, active caspase-3 staining was found to be strongest in
close proximity to tumor cells with an epithelial phenotype (CK14-
positive cells; Figure 7c). Staining for cleaved caspase-3 was
Figure 4. HER2 overexpression leads to loss of growth arrest in monolayer and increased survival in low attachment. (a) D492HER2 cells have
lost contact inhibition in monolayer culture. D492 cells expressing ctrl, HER2, EGFR and HER2/EGFR were seeded on 24-well plates and cell
proliferation measured bi-daily by trypsinizing cells, counting and measuring viability. (b) HER2 leads to higher colony formation in low
attachment. D492 cells expressing ctrl, HER2, EGFR and HER2/EGFR were seeded on low-attachment plates and colonies were counted.
Bar= 200 μm.
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limited in control and EGFR tumors (Supplementary Figure S3B),
indicating low levels of apoptosis.
Collectively, these data showed that coexpression of EGFR and
HER2 resulted in slower tumor growth than HER2 alone and
suggested that EGFR might suppress the oncogenic properties of
HER2, through maintenance of the epithelial phenotype.
DISCUSSION
Overexpressing two oncogenes, HER2 and EGFR, in the D492
breast epithelial progenitor cell line resulted in changed cellular
phenotypes. D492HER2 underwent EMT as evidenced by loss of
epithelial markers, and gain of mesenchymal markers accompa-
nied by formation of spindle-like colonies in 3D rBM culture.
Furthermore, D492HER2 cells showed tumorigenic properties
in vivo. These ﬁndings are in concordance with other studies
where loss of cytokeratins and epithelial cadherins following HER2
Figure 5. EGFR partially reverses HER2-induced EMT in 3D culture.
(a) D492HER2 cells show disrupted branching morphogenesis and
generate spindle- and grape-like colonies in 3D culture. D492 cells
expressing ctrl, HER2, EGFR and HER2/EGFR were seeded into rBM
and cultured for 2 weeks. Top picture panel shows representative
bright-ﬁeld images of branching structures found in 3D organotypic
cultures of D492 cells. Bar= 100 μm. Representative isolated
structures were ﬁxed and stained for E- and N-cadherin, CK14 and
CK19. Bar= 50 μm. After the culture period, colonies were counted
into four groups, branching/budding, solid round, grape like and
spindle. The left table demonstrates the frequencies of each of these
phenotypic groups within each D492 subline. The right table
demonstrates the same ratios when cultures were treated with the
small-molecule HER2 inhibitor CP724,714. (b) EGFR restores the
epithelial phenotype in 3D culture in D492HER2 (D492HER2/EGFR).
Western immunoblot for E- and N-cadherin, CK14 and Ck19 of
protein lysates isolated from 3D cultures after 14 days of cultivation.
Figure 6. Overexpression of HER2 in D492 leads to increased tumor
growth in NSG mice which is partially reversed by EGFR signaling.
(a) D492HER2 and D492HER2/EGFR generate tumors efﬁciently in NSG
mice. D492 cells expressing ctrl, HER2, EGFR and HER2/EGFR were
injected into NSG mouse mammary fat pads. Numbers represent
appearance palpable tumors over total number over injections
performed during the course of the experiment. (b) EGFR negatively
affects HER2-induced tumor growth. Changes to tumor volumes of
D492 cell lines. (c) Cetuximab reduces trastuzumab sensitivity in
D492HER2 tumors. D492HER2 cells were allowed to form tumors in NSG
mice. After 2 weeks, mice were randomized into four groups and
treated with trastuzumab, cetuximab and a combination of both
drugs. Changes to tumor volumes were measured two times weekly.
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overexpression has been described.19–21 HER2 has previously also
been overexpressed in non-tumorigenic mammary epithelial
cells.22,23 In the present study we conﬁrmed that HER2 activity
was necessary for the tumor-initiating ability and that simulta-
neous expression of EGFR suppresses the oncogenic activity of
HER2 by maintaining epithelial integrity.
There are a number of studies showing that myoepithelial cells
can act as tumor suppressors in the breast gland (reviewed by
Barsky et al.24). Myoepithelial cells maintain the correct polarity of
luminal epithelial cells by providing basement membrane proteins
such as laminins.5 In cancer, the transition from ductal carcinoma
in situ to invasive carcinoma is among other things characterized
by the progressive loss of myoepithelial cells.25 Forster et al. have
recently shown that p63 positive myoepithelial cells are important
regulators of epithelial integrity in the breast gland. Loss of p63
resulted in failure of luminal epithelial cells to lactate, due to a
failure of myoepithelial cells to express the EGF family member
neuregulin.26 Interestingly, HER2 overexpression in our model
Figure 7. EGFR expression reverses HER2-induced loss of cytokeratin expression in xenografts tumors. (a) Mosaic picture of sections from H&E
staining of D492HER2 and D492HER2/EGFR tumors. Tumors were parafﬁn embedded, sliced and stained with H&E. Squares denote areas
represented in immunoﬂuorescence in (b). Bar= 1mm. (b) EGFR reverses HER2-induced loss of cytokeratin expression. Confocal images
showing xenograft slices from D492HER2 and D492HER2/EGFR tumors stained with HER2, EGFR, CK14 and E-cadherin. Bar= 100 μm. (c) Apoptosis
levels are higher in close proximity to epithelial, CK14-expressing tumor areas. Confocal images showing xenograft slices from D492HER2 and
D492HER2/EGFR tumors stained with CK14, Ki67 and cleaved caspase-3 antibodies. Bar= 100 μm.
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prompted a clear decline in EGFR transcription, coinciding with
loss of all epithelial markers. One can speculate if the loss of EGFR,
which is a driver of myoepithelial differentiation, allowed the more
aggressive HER2-expressing cells to proliferate. Supporting this, a
loss of EGFR expression accompanied by gain of other EGFR family
members during breast cancer progression has been previously
described,27 and predicted to be a response to changes in HER
receptor family downstream signaling, such as estrogen receptor
(ER). Indeed, ER status negatively correlates with EGFR expression,
as EGFR is often highly expressed in TNBC,28 while HER2 is
positively correlated with ER.29 Our data might indicate that HER2,
but not ER, is affecting EGFR expression and phosphorylation. In a
recent paper, Wheeler et al. analyzed the correlation between total
EGFR, pY1068EGFR expression/phosphorylation and prognosis in
head and neck cancer. They demonstrated that total EGFR and
pY1068EGFR were prognostic markers in both early stage
detected cancers and cetuximab-treated cancers. Furthermore,
they also demonstrated that pY1068 was an independent
negative factor even when the total EGFR expression was low.
This is partially in line with our data, where D492-overexpressing
HER2 or HER2/EGFR show low expression of total EGFR but
increased phosphorylation of Y1068EGFR. The mechanisms
connecting increased Y1068 phosphorylation and reduced tumor-
igenicity in EGFR/HER2-expressing D492 cells, however, remain to
be elucidated.
Although total EGFR expression is lowered we see increased
relative phosphorylation levels of Y1068EGFR. EGFR is frequently
ubiquitinated and sorted for intracellular degradation.30,31 Unlike
EGFR, HER2 largely evades ubiquitination, and undergoes inter-
nalization and recycling, which prolongs signals generated by
HER2-containing heterodimers.32,33 Another mechanism that
enables HER2 to enhance signaling, despite its inability to directly
bind a ligand growth factor, includes inhibition of EGF dissociation
from HER2-containing heterodimers.34–36
The importance of EGFR expression for preserving the epithelial
phenotype was underscored in the experiments where EGFR was
re-introduced in D492HER2 (D492HER2/EGFR). The in vivo experiments
showed that D492HER2/EGFR tumors grew slower than D492HER2 and
the resulting tumors were heterogeneous with a mixed epithelial
and mesenchymal phenotype, data that were well supported in
the 3D organotypic culture experiments. In addition, treatment of
D492HER2 xenografts with HER2 and EGFR monoclonal antibodies
(trastuzumab and cetuximab, respectively) showed that inhibition
of the small EGFR activity found in HER2 xenografts reduced the
efﬁcacy of trastuzumab. These data indicated that when expressed
in conjunction with HER2, EGFR might act as a tumor suppressor
by preserving epithelial differentiation. This result is contrary to
what was previously found in xenografts from BT20 mammary
epithelial cells overexpressing HER2, where downregulation of
EGFR slowed tumor growth.23 The importance of context when
investigating HER2-induced effects was emphasized by the
differences between 2D and 3D culture. In 2D (monolayer) of
double expressing D492 cells (D492HER2/EGFR), the HER2-associated
phenotype was dominant over the EGFR phenotype, as evidenced
by complete loss of epithelial markers. Interestingly, in 3D assays
(and in vivo), EGFR partially reversed the EMT phenotype caused
by HER2. These results suggest that 3D organotypic cultures are
excellent mimickers of HER2 interactions in vivo, and that
microenvironmental context is crucial for what effects HER2
overexpression have on the cellular phenotype.
Understanding the lineage relationship between luminal- and
myoepithelial cells in the human breast gland is important to be
able to recognize how the normal gland is maintained, how the
different subgroups of breast cancer occur and how different
clinical outcomes are related to the particular phenotype. In this
study, it has been shown that HER2 and EGFR are expressed in
luminal- and myoepithelial cells, respectively. In the HER2 subtype
of breast cancer, the ErbB2 gene is ampliﬁed; expression (although
not ampliﬁed) of HER2 can also be found in other subtypes such
as luminal B and even TNBC.37 Balk-Møller and colleagues38 have
recently demonstrated that HER2-rich tumors and luminal tumors
likely share a common origin. This correlates well with the fact that
HER2 was predominately expressed in the luminal compartment
of human mammary epithelial structures. A large number of
luminal B tumors express HER2. Luminal B tumors, although
positive for ER, do not respond to tamoxifen treatment and have
a worse prognosis than luminal A tumors.39 The D492 cell line
originated from suprabasal cells has a basal-like expression
pattern and is not dependent on estrogen, but is highly
dependent on EGF for growth. EGFR, along with CK5/6 are the
key markers used to identify basal-like breast cancer within TNBC.
Basal-like breast cancers, and especially the claudin-low subtype,
have been associated with the mesenchymal phenotype.40 The
EMT program has been associated with many invasive cancer
types. This process is seen as an escape pathway for cancer cells to
invade the adjacent tissue and subsequently migrate into the
lymphatic or blood system.41,42 It is, however, important to
discriminate between partial EMT where cells retain large part of
their epithelial properties and complete EMT where epithelial cells
lose their epithelial properties and adopt a complete mesench-
ymal differentiation state. The latter is one of the hallmarks of
cancer.43 Interestingly, HER2 overexpression clearly led to a
complete EMT with loss of all epithelial markers, downregulation
of miR-200c-141 and increased expression of ZEB1. Tumor cells
with a mesenchymal phenotype are described as highly
aggressive and more resistant to treatment than other cancer cell
populations.44,45 In the event that HER2 is the initiator of the
aggressive mesenchymal phenotype, therapy regimes might
become more effective and less exposed to resistance if they
are designed to both inhibit HER2 and the mesenchymal
phenotype. Interestingly, even a very low expression of EGFR
and low EGFR activity was sufﬁcient to counteract HER2-induced
EMT and reintroduce cytokeratin expression in 3D culture and
in vivo. The signaling events upheld by EGFR might represent
attractive possibilities for anti-HER2 and anti-EMT therapy.
In this work, we have explored the roles of HER2 and EGFR in
mammary progenitor cells. The data introduced a novel role for
EGFR in breast morphogenesis and cancer; if expressed in a
deﬁned context with HER2, EGFR may act as a tumor suppressor
by maintaining epithelial integrity. These data indicate that in
certain tumors, where EGFR expression is present, inhibiting the
receptor might lead to changes in marker expression and loss of
epithelial characteristics, emphasizing the importance of context
when devising treatment strategies.
MATERIALS AND METHODS
Cell culture
D492 cells were maintained in H14 media as described previously,17 in
tissue culture treated, collagen I (Advanced Biomatrix, San Diego, CA, USA)-
coated T25 Falcon ﬂasks (BD Biosciences (BD), Franklin Lakes, NJ, USA).
The cells were subcultured weekly in a 1:20 ratio in new ﬂasks. Cells were
fed three times per week and routinely checked for mycoplasma
contamination
Immunohistochemistry
Cryosections from fresh-frozen tissue samples from reduction mammo-
plasties (Icelandic National Bioethics Committee No. VSN-13-057) or 3D
experiments were ﬁxed in 3.7% formaldehyde for 15min and permeabi-
lized with 0.1% Triton-X for 10min. Samples were blocked using 5%
normal goat serum (Life Technologies, Carlsbad, CA, USA) and incubated
with primary antibody overnight at 4 °C. Samples were then stained with
isotype speciﬁc secondary ﬂuorescent Alexa Fluor goat antibodies
(Life Technologies) and counterstained with 4',6-diamidino-2-phenylindole
(DAPI) (Sigma-Aldrich, St Louis, MO, USA). Samples were visualized using
an Olympus FV1200 Confocal microscope (Olympus, Tokyo, Japan).
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Sections from parafﬁn-embedded mouse tissue were processed in
xylene and ethanol to remove parafﬁn, and then rehydrated in dH2O. After
rehydration, high-temperature antigen retrieval was performed. Samples
were stained as described above.
Antibodies used for immunostaining/western blotting
The following antibodies were used in this study: CK14 (Leica Micro-
systems, Wetzlar, Germany, LL-002 and Abcam, Cambridge, UK, ab 15461),
CK19 (Abcam, ab7754), Actin (Abcam ab8229), glyceraldehyde 3-phos-
phate dehydrogenase (Abcam, ab9484), p63 (Abcam, ab3239), E-cadherin
(BD, BD610682), N-cadherin (BD, BD610921), P-cadherin (Cell Signaling
(CS), Danvers, MA, USA, #2130), EGFR (CS#4267), EGFR pY1068 (CS#3777),
EGFR pY1173 (CS#4407), HER2 (CS#2165) HER2 pY1221/1222 (CS#2243), Axl
(CS#8661), Ki67 (Abcam, ab15580), Cleaved Caspase-3 (Abcam, ab2302)
and Phalloidin (Life Technologies, A22283, A12379).
Viral transduction
All vectors used for viral production or cloning were acquired from
Addgene and are shown in Supplementary Figure S1. pBABE-EGFR and
empty backbone (#11011, #1764, respectively46) were used as provided.
HER2 coding sequence (#1625747) was cloned into the lentiviral vector
pWPI (#12254, gift from Didier Trono). Retroviral (EGFR) virus production
was performed in Phoenix HEK293 cells, using Arrestin transfection
(Life Technologies). D492 cells were infected overnight with viral
supernatant containing 8 μg/ml Polybrene (Sigma-Aldrich). EGFR-
transduced cells were selected using 2 μg/ml puromycin (Sigma-Aldrich).
HER2-containing lentiviral plasmids were transfected into HEK293T cells
using ArrestIn, and D492 cells were infected with viral supernatant
containing 8 μg/ml polybrene. HER2-overexpressing cells were selected
based on eGFP expression in FACSaria (BD). Control cells were transduced
with both empty vector backbones for EGFR and HER2.
Primary cultures
For western blotting we isolated normal primary mammary cells from
reduction mammoplasties. Donor material was given after acquiring
informed consent from the donor. Approved by the Icelandic National
Bioethics Committee VSN-13-057.
Primary normal human mammary tissue was processed as previously
described.48 Luminal epithelial cells were sorted by positive selection
or MUC1 (Life Technologies) and EpCAM (Leica) using magnetic cell
sorting (Miltenyi Biotech, Bergisch Gladbach, Germany), whereas
myoepithelial cells were selected for using Thy-1 (Dianova, Hamburg,
Germany) and subsequently with beta 4 integrin (Millipore, Billerica,
MA, USA) selection.
3D assays
For 3D assays, 104 cells were seeded into 300 μl Matrigel (BD) and
maintained over 15 days. Culture media (H14) was changed three times
per week. After the culture period, cultures were processed for protein
extraction or immunostaining of isolated colonies as described by Lee
et al.49 For experiments when cells were treated with the HER2 inhibitor
CP724,714, media was supplemented with a ﬁnal concentration of 100 nM
inhibitor dissolved in dimethyl sulfoxide.
Proliferation assay
Cells were seeded in triplicate into collagen-coated six-well trays at a
density of 50 000 cells per well in H14 media. Every other day, cells were
detached and combined with the ﬂoating fraction from the spent media.
Cells were then stained with Acridine Orange and DAPI (both from
Chemometec A/S, Allerod, Denmark): staining all cells and dead cells,
respectively. Viable and dead cells were counted using NucleoCounter-
3000 (Chemometec)
Western blotting
Protein lysates were acquired using RIPA lysis buffer supplemented
with both phosphatase and protease inhibitor cocktails (Life Technolo-
gies). For western blots, 5 μg protein was used per lane, unless otherwise
stated. Samples were denatured using 10% mercaptoethanol at 95 °C
for 5 min and run on NuPage 10% Bis-Tris gels (Life Technologies) in
2-(N-morpholino)ethanesulfonic acid (MES) running buffer. Samples
were then transferred to Immobilon FL PVDF membranes (Millipore).
Membranes were blocked in Li-cor blocking buffer and primary
antibodies were incubated overnight at 4 °C. Near-infrared ﬂuorescence
visualization was measured using Odyssey CLx scanner (Li-Cor,
Cambridge, UK).
Low attachment assay
For low-attachment assays, six-well trays were coated with 1.2 mg/ml poly-
HEMA (Sigma-Aldrich) overnight at 37 °C. Cells were seeded in triplicate at
a density of 103 per well, and cultured for 2 weeks. After the culture period,
colonies were imaged and counted.
Quantitative reverse transcriptase–PCR
Total RNA was extracted with Trizol (Life Technologies), DNAase
treated and reverse transcribed with hexanucleotides using ReverAid
(#K1622, Life Technologies). Resulting cDNA was used for quantitative
reverse transcriptase–PCR, in master mix (Life Technologies) with primer
pairs and probes for EGFR (Hs00540086_m1, Life Technologies),
HER2 (Hs01076092_m1), ZEB1 (Hs00232783_m1) and glyceraldehyde
3-phosphate dehydrogenase (Hs99999905_m1). Experiments were carried
out in triplicate on 7500 Real Time PCR System (Life Technologies). EGFR,
HER2 and ZEB1 mRNA levels were normalized to glyceraldehyde
3-phosphate dehydrogenase and relative mRNA differences were calcu-
lated with the 2ΔCt method.
Quantitative reverse transcriptase–PCR analysis of miRNAs was per-
formed using miRCURY LNA microRNA PCR System (Exiqon, Copenhagen,
Denmark). Gene expression levels were quantiﬁed using primers for
hsa-miR-141 (#204504) and hsa-miR-200c (#2044852) (Exiqon). Normal-
ization was carried out with U6 RNA(#203907)(Exiqon).
NSG xenografts
The in vivo tumorigenicity assays were performed using NOD/SCID
interleukin-2 receptor gamma chain null (NSG Il2rg− / − ) mice, under
unblinded conditions. The animals (n = 23) were randomized into four
groups according to size, and 5 × 105 cells were injected bilaterally in
100 μl phosphate-buffered saline/matrigel. Group sizes were as follows:
D492ctrl, n = 5; D492EGFR, D492HER2 and D492HER2/EGFR, n= 6 for each
group. Distilled tap water was given ad libitum, supplemented with
17-β-estradiol at a concentration of 4 mg/l. For drug experiments,
23 mice were injected bilaterally with 5x105 D492HER2 cells. Mice were
treated intraperitoneally with 4 mg/kg trastuzumab, 20 mg/kg cetuximab
or a combination of the two (n = 6 for each group, n= 5 for control mice)
from day 0 (13 days post injection), once a week on days 0, 7, 14 and 21.
All mice used in the experiment were locally bred at the Department of
Comparative Medicine (Oslo University Hospital, Oslo, Norway).
All procedures and experiments involving animals were approved by
the National Animal Research Authority (http://www.fdu.no/).
The experiments were conducted according to the regulations of the
Federation of European Laboratory Animal Science Association (FELASA),
and performed according to the 3R principle (Replacement, Reduction,
and Reﬁnement). Mice were killed before the end of the experiment if
tumor size exceeded 20 mm diameter, or if mice appeared unhealthy or
in pain. Tumors were measured two times weekly, and after the
experimental period, tumors were harvested, formalin ﬁxed and
embedded in parafﬁn.
Statistical analysis
All experiments were performed at minimum in triplicate. Graphs were
generated in Microsoft Excel. Error bars represent the standard deviation of
the mean.
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